SCNX News & Events

Scienture announced that it has formalized multiple commercial Group Purchasing Organization, GPO, agreements for Rezenopy Nasal Spray 10 mg, providing access to more than 5000 healthcare institutions, including hospitals, clinics and nursing homes, representing potential penetration into roughly 60% of the U.S. institutional market while also establishing a broad footprint across first responders, EMS providers and rehabilitation centers. "These GPO agreements represent a significant step forward in the commercial expansion of Rezenopy," commented Narasimhan Mani, President and co-CEO of Scienture. "They meaningfully expand our institutional reach, providing access to more than 5000 healthcare facilities representing potential penetration into approximately 60% of the U.S. institutional market. With the U.S. naloxone market representing approximately $141 million in annual sales and 9.4 million prescription units, we believe Rezenopy, the highest-dose FDA-approved naloxone nasal spray, is well positioned to drive broader adoption and capture market share as we continue executing our commercialization strategy."

Scienture provided a commercial update on Arbli oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook-including reaffirming its plan to commercially launch Rezenopy, a life-saving opioid overdose emergency treatment, in the second quarter of 2026. Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to Arbli across retail, institutional, and managed care channels within the approximately $241 million in total annual sales and 72 million prescriptions U.S. losartan market.